April 1, 2008Chemical Research in Toxicology
Cardiotoxicity of Antitumor Drugs
Population
Patients receiving antitumor drugs, including chemotherapeutics and targeted therapies
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May refine cardio-oncology risk stratification; leaves open prospective validation before guiding practice.
Structured PICO
P
Population
Patients receiving antitumor drugs, including chemotherapeutics and targeted therapies
I
Intervention
Antitumor drugs (including doxorubicin, other anthracyclines, and targeted drugs like Trastuzumab)
O
Outcome
Cardiotoxicity (congestive heart failure and other cardiovascular events)safety
The review highlights the mechanisms of antitumor drug-induced cardiotoxicity and supports a classification system (Type I vs Type II) to improve early identification and minimize cardiac risks in cardio-oncology.
Cite This Study
Menna et al. (2008) studied this question.